If there's no insurance coverage, then generally the conversation is over.
A new class of medications has emerged with the power to reshape how medicine treats obesity — yet in 2023, only a fraction of those who might benefit ever received them. In the United States, where half of all adults live with obesity and its cascading health consequences, access to semaglutide and similar drugs has become a mirror held up to the nation's deepest inequities: of race, income, geography, and how society chooses to define which suffering deserves relief. The revolution, as one physician put it, exists — it is simply not arriving where it is most needed.
- Drugs clinically proven to treat obesity, heart disease risk, and diabetes remain out of reach for the vast majority of Americans who need them, blocked not by medicine but by a $1,000-per-month price tag and routine insurance denials.
- The disparity cuts along familiar fault lines — 85% of semaglutide prescriptions in 2023 went to white patients, while Black Americans, who carry disproportionately higher rates of obesity and diabetes, received roughly 12%.
- Physicians describe a quiet crisis in their exam rooms: patients who have exhausted every other option are being turned away not by their doctors, but by insurers and a 2003 law that bars Medicare from covering weight loss drugs entirely.
- Some pressure points are shifting — the FDA's expanded approval of Wegovy for heart disease prevention may force insurers to reconsider, and a growing share of employers are beginning to offer coverage.
- But without action on manufacturer pricing and the absence of market competition, advocates and clinicians warn that incremental policy changes will leave the most vulnerable populations exactly where they are.
In her Norman, Oklahoma clinic, Dr. Laure DeMattia listens to patients recount every diet they have ever tried. She can write a prescription for semaglutide or tirzepatide — the drugs now widely regarded as transformative treatments for obesity. What she cannot do is make them affordable.
In 2023, just 1% of insured Americans filled a semaglutide prescription, even as roughly half of all American adults live with obesity or severe obesity. The drugs exist. The need is vast. The gap between them is measured almost entirely in dollars and denied claims.
The disparities are not subtle. An analysis of more than four million prescriptions found that 85% went to white patients, while Black Americans — who face significantly higher rates of both obesity and diabetes — received around 12%. Oklahoma, with one of the highest adult obesity rates in the country, barely registers among states where the drugs are actually being used. West Virginia briefly bucked the trend by covering the cost for state employees, but that coverage ended in February.
The core obstacle is a monthly cost of roughly $1,000, compounded by a 2003 federal law that prohibits Medicare from covering weight loss drugs at all. Many private insurers follow suit, still treating obesity as a cosmetic concern rather than a chronic disease. Liz Shumate, a 41-year-old therapist in Oklahoma City, was denied coverage for Wegovy despite wanting to reduce her heart disease risk. Susan Beam, 67, is on Medicare and cannot access a medication her doctors say could help her blood pressure and arthritis. Both women understand what is at stake. Both have been told no.
Physicians across the country describe the same erosion of possibility. Patients stop coming to appointments after their prescriptions are denied. Conversations about treatment end the moment insurance is off the table. "If there's no insurance coverage, then generally the conversation is over," one physician said.
There are faint signs of movement. The FDA's recent expansion of Wegovy's approval to include heart disease prevention has reopened the policy debate, and federal regulators are reviewing whether Medicare coverage should follow. A growing share of employers are beginning to cover the drugs. But the insurance industry itself has acknowledged that without action on pricing and competition, these shifts will not be enough.
Shumate framed the contradiction plainly: insurers will cover open-heart surgery, but not the medication that might prevent it. The treatment exists. The question now is whether the systems meant to protect public health will choose to make it available to the people who need it most.
Dr. Laure DeMattia sits across from her patients in Norman, Oklahoma, and watches them describe the diets they've already tried. Weight Watchers. Nutrisystem. High protein, low carb. Everything they thought was physically possible to alter through willpower alone. What they haven't tried—what most of them will never try—is a monthly injection of semaglutide or tirzepatide, the drugs that have been hailed as revolutionary treatments for obesity. DeMattia can write the prescription. What she cannot do is make it affordable.
The weight loss drug revolution, it turns out, is not for most Americans. In 2023, only 1% of the U.S. population with government or private insurance filled a prescription for semaglutide, the most popular of these medications. About half of all American adults have obesity or severe obesity—a public health crisis that increases the risk of heart disease, diabetes, and certain cancers. Yet the drugs that could help them remain largely out of reach, blocked not by medical barriers but by cost and insurance denial.
The disparities are stark and troubling. An analysis of more than 4 million semaglutide prescriptions written nationwide in 2023 found that 85% went to white patients. Black Americans, who have significantly higher rates of both diabetes and obesity, received around 12% of the prescriptions. Geography matters too. Oklahoma, with an adult obesity rate of 40%—the third highest in the nation—doesn't even rank in the top 25 states for semaglutide prescriptions. West Virginia, which has the highest obesity rate in the country, ranks second for prescriptions, largely because the state covered the cost for its employees. That coverage ended in February.
The barrier is simple and brutal: the drugs cost around $1,000 per month. Insurance companies typically refuse to pay, or when they do, erect high barriers to authorization. A 2003 law prohibits Medicare from covering weight loss drugs entirely, cutting off millions of older Americans and setting a precedent that private insurers often follow. Many insurers still view obesity as a cosmetic issue rather than a chronic disease, even as the medical evidence has shifted. Liz Shumate, a 41-year-old mental health therapist from Oklahoma City who is Black, wanted to lose 20 pounds to reduce her risk of heart disease. Her employer's insurance denied coverage for Wegovy. She cannot afford the monthly cost. Susan Beam, 67, is on Medicare and wants a weight loss medication her doctors say could help her high blood pressure and rheumatoid arthritis. Medicare denies coverage. She cannot afford it either.
Dr. Peminda Cabandugama, an endocrinologist at the Cleveland Clinic, describes the current landscape bluntly: obesity management has become something done mostly for people with better insurance. Dr. Ryan Morgan, an obesity medicine physician in Oklahoma, tells his patients the truth—that insurance will almost certainly deny their claims. "It feels like my tools are being taken away from me," he said. Dr. Drake Bellanger, an obesity specialist in Louisiana, watches patients stop showing up for appointments after their prescriptions are denied. They give up. Dr. Laura Davisson at West Virginia University has seen this pattern repeatedly. "If there's no insurance coverage, then generally the conversation is over," she said.
There are signs of possible change. The FDA recently expanded approval of Wegovy to reduce heart attack and stroke risk, moving the conversation beyond weight loss alone. The Centers for Medicare & Medicaid Services is reviewing this expanded indication. Some employers are beginning to cover the drugs—41% according to a 2023 report. But the insurance industry's trade group acknowledged that manufacturers' pricing of more than $1,000 per month and lack of competition remain barriers that cannot be overcome without intervention.
The human cost is measured in patients who have tried everything else, who understand the stakes for their health, and who are told no. Shumate posed the question that haunts this moment: "When we think about people being able to manage their weight in a healthy way that leads to better outcomes long term, it just doesn't make sense. There's an explanation for not covering it through insurance, but then we'll cover open-heart surgery, or we'll cover other lifesaving measures. Why don't we invest that money on the front end?" The revolution in weight loss treatment exists. It is simply not available to the people who need it most.
Citas Notables
My patients have already done Weight Watchers, Nutrisystem. They've already done as much as they thought was physically possible to alter their diet and exercise.— Dr. Laure DeMattia, bariatric medicine specialist in Norman, Oklahoma
When we think about people being able to manage their weight in a healthy way that leads to better outcomes long term, it just doesn't make sense. Why don't we invest that money on the front end?— Liz Shumate, 41-year-old mental health therapist denied coverage for weight loss drugs
La Conversación del Hearth Otra perspectiva de la historia
Why does a drug that works so well remain so inaccessible? It seems like a straightforward business problem.
It's not really a business problem—it's a policy problem. The drugs work, manufacturers charge what the market will bear, and insurers calculate that paying $12,000 a year per patient is too expensive. But they're making that calculation without considering what happens when you don't treat obesity: heart attacks, strokes, amputations, dialysis. The math only works if you're looking at one year, not a lifetime.
So why don't insurers see it that way?
Because obesity has been treated as a personal failing for so long that it's still not coded in most insurance systems as a disease that deserves prevention spending. A 2003 law literally forbids Medicare from covering these drugs. That's not based on evidence—it's based on old assumptions about what obesity is.
The racial disparity is striking. Why would white patients get 85% of prescriptions?
It's not that doctors are deliberately excluding Black patients. It's that access follows money and insurance. If your employer covers it or you can pay out of pocket, you get it. Black Americans are more likely to be uninsured or underinsured, more likely to be on Medicare, and less likely to have employers offering robust coverage. The disparity is structural, not individual.
What happens to a patient when insurance denies them?
They stop coming. They've already tried everything else—diet, exercise, other medications. When the thing that could actually work is denied, many just accept that this is how their life will be. Some gain the weight back. Some develop the complications they were trying to prevent. It's not dramatic, but it's final.
Is there any scenario where this changes?
Yes, if the FDA's new indication for heart disease prevention forces insurers to recalculate the cost-benefit. Or if Congress changes the 2003 law. Or if manufacturers lower prices. But right now, none of those things are happening fast enough for the people sitting in Dr. DeMattia's office.